Tafamidis

Pharma

Is Pfizer's recent ATTR sales decline in the US a warning sign?

Pfizer's tafamidis U.S. sales decline could be a concerning sign, because the market is said to be large enough for multiple players to grow together.

Angus Liu Dec 2, 2025 8:20am

Pfizer to discontinue low-dose ATTR drug Vyndaqel in US in 2025

Aug 29, 2025 10:40am

Space shuttle takes off on background of blue sky

Alnylam's market cap jumps past $50B

Aug 1, 2025 7:39am

Pfizer's ATTR drug again faces pricing scrutiny

Oct 21, 2024 2:55pm

Alnylam sees Amvuttra as potential standard of care in ATTR-CM

Aug 30, 2024 10:06am

Pfizer's ATTR drug needs hefty discount, says ICER draft report

Jul 18, 2024 4:37pm